NASDAQ:PRNB

Principia Biopharma (PRNB) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$100.05
$100.05
50-Day Range
$99.95
$100.27
52-Week Range
$25.35
$101.89
Volume
N/A
Average Volume
729,676 shs
Market Capitalization
$3.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PRNB stock logo

About Principia Biopharma Stock (NASDAQ:PRNB)

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.

PRNB Stock News Headlines

Principia College names new president
Never use this word on your phone (FBI could be watching)
This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...
Principia Biopharma Inc (PRNB)
Never use this word on your phone (FBI could be watching)
This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...
Lebanon's Skobel signs with Principia
Principia College earns honors
See More Headlines
Receive PRNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Principia Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2020
Today
5/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRNB
CIK
N/A
Fax
N/A
Employees
65
Year Founded
N/A

Profitability

Net Income
$-53,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$35.16 million
Book Value
$10.95 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.32 billion
Optionable
Not Optionable
Beta
0.86
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Alan B. Colowick Ph.D. (Age 57)
    M.D., M.P.H., Exec. Chairman
  • Mr. Martin BablerMr. Martin Babler (Age 54)
    CEO & Director
  • Mr. Christopher Y. Chai (Age 52)
    Chief Financial Officer
  • Ms. Stefani A. Wolff (Age 57)
    Chief Devel. Officer
  • Dr. David M. Goldstein (Age 53)
    Chief Scientific Officer

PRNB Stock Analysis - Frequently Asked Questions

How were Principia Biopharma's earnings last quarter?

Principia Biopharma Inc. (NASDAQ:PRNB) posted its quarterly earnings results on Thursday, August, 6th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of ($1.03) by $1.34. The company had revenue of $50 million for the quarter, compared to the consensus estimate of $50 million.

What other stocks do shareholders of Principia Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Gilead Sciences (GILD), Micron Technology (MU), QUALCOMM (QCOM), VBI Vaccines (VBIV), ImmunoGen (IMGN) and Taiwan Semiconductor Manufacturing (TSM).

When did Principia Biopharma IPO?

Principia Biopharma (PRNB) raised $75 million in an IPO on Friday, September 14th 2018. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

This page (NASDAQ:PRNB) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners